ELIAS JOSEPH JABBOUR to Recurrence
This is a "connection" page, showing publications ELIAS JOSEPH JABBOUR has written about Recurrence.
Connection Strength
3.480
-
Safety and long-term survival results of the addition of inotuzumab ozogamicin to the conditioning regimen of allogeneic stem cell transplantation: A single-center phase 1,2 trial. Am J Hematol. 2024 May; 99(5):836-843.
Score: 0.131
-
Phase 2 study of inotuzumab ozogamicin for measurable residual disease in acute lymphoblastic leukemia in remission. Blood. 2024 Feb 01; 143(5):417-421.
Score: 0.131
-
High-sensitivity next-generation sequencing MRD assessment in ALL identifies patients at very low risk of relapse. Blood Adv. 2022 07 12; 6(13):4006-4014.
Score: 0.117
-
Chronic myeloid leukemia: 2022 update on diagnosis, therapy, and monitoring. Am J Hematol. 2022 Sep; 97(9):1236-1256.
Score: 0.117
-
Blinatumomab is associated with favorable outcomes in patients with B-cell lineage acute lymphoblastic leukemia and positive measurable residual disease at a threshold of 10-4 and higher. Am J Hematol. 2022 Sep; 97(9):1135-1141.
Score: 0.117
-
Intrathecal prophylaxis with 12 versus 8 administrations reduces the incidence of central nervous system relapse in patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia. Am J Hematol. 2023 01; 98(1):E11-E14.
Score: 0.117
-
Genetic correlates in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with Hyper-CVAD plus dasatinib or ponatinib. Leukemia. 2022 05; 36(5):1253-1260.
Score: 0.114
-
Long-term outcome of hyper-CVAD-R for Burkitt leukemia/lymphoma and high-grade B-cell lymphoma: focus on CNS relapse. Blood Adv. 2021 10 26; 5(20):3913-3918.
Score: 0.112
-
Discontinuation of Maintenance Tyrosine Kinase Inhibitors in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia outside of Transplant. Acta Haematol. 2021; 144(3):285-292.
Score: 0.105
-
Outcome of adults with relapsed/refractory T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma. Am J Hematol. 2020 09; 95(9):E245-E247.
Score: 0.103
-
Treatment-free remission in chronic myeloid leukemia. Clin Adv Hematol Oncol. 2019 Dec; 17(12):686-696.
Score: 0.098
-
Impact of minimal residual disease status in patients with relapsed/refractory acute lymphoblastic leukemia treated with inotuzumab ozogamicin in the phase III INO-VATE trial. Leuk Res. 2020 01; 88:106283.
Score: 0.098
-
Chemoimmunotherapy with inotuzumab ozogamicin combined with mini-hyper-CVD, with or without blinatumomab, is highly effective in patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in first salvage. Cancer. 2018 10 15; 124(20):4044-4055.
Score: 0.090
-
Incorporating Immunotherapy Into the Treatment Strategies of B-Cell Adult Acute Lymphoblastic Leukemia: The Role of Blinatumomab and Inotuzumab Ozogamicin. Am Soc Clin Oncol Educ Book. 2018 May 23; 38:574-578.
Score: 0.088
-
Salvage Chemoimmunotherapy With Inotuzumab Ozogamicin Combined With Mini-Hyper-CVD for Patients With Relapsed or Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Phase 2 Clinical Trial. JAMA Oncol. 2018 Feb 01; 4(2):230-234.
Score: 0.086
-
Outcome of patients with relapsed/refractory acute lymphoblastic leukemia after blinatumomab failure: No change in the level of CD19 expression. Am J Hematol. 2018 03; 93(3):371-374.
Score: 0.086
-
Treatment of adult acute lymphoblastic leukemia with inotuzumab ozogamicin. Future Oncol. 2017 Oct; 13(25):2233-2242.
Score: 0.083
-
Factors associated with risk of central nervous system relapse in patients with non-core binding factor acute myeloid leukemia. Am J Hematol. 2017 Sep; 92(9):924-928.
Score: 0.083
-
Outcomes of adults with relapsed or refractory Burkitt and high-grade B-cell leukemia/lymphoma. Am J Hematol. 2017 06; 92(6):E114-E117.
Score: 0.082
-
Management of Relapsed/Refractory Acute Myeloid Leukemia in the Elderly: Current Strategies and Developments. Drugs Aging. 2015 Aug; 32(8):623-37.
Score: 0.073
-
Prognostic factors for outcome in patients with refractory and relapsed acute lymphocytic leukemia treated with inotuzumab ozogamicin, a CD22 monoclonal antibody. Am J Hematol. 2015 Mar; 90(3):193-6.
Score: 0.070
-
Twice-daily fludarabine and cytarabine combination with or without gentuzumab ozogamicin is effective in patients with relapsed/refractory acute myeloid leukemia, high-risk myelodysplastic syndrome, and blast- phase chronic myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2012 Aug; 12(4):244-51.
Score: 0.058
-
Central nervous system prophylaxis in adults with acute lymphoblastic leukemia: current and emerging therapies. Cancer. 2010 May 15; 116(10):2290-300.
Score: 0.051
-
Low-dose azacitidine after allogeneic stem cell transplantation for acute leukemia. Cancer. 2009 May 01; 115(9):1899-905.
Score: 0.047
-
Allogeneic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after Bcr-Abl kinase mutation-related imatinib failure. Blood. 2006 Aug 15; 108(4):1421-3.
Score: 0.038
-
Phase I Results of Bromodomain and Extra-Terminal Inhibitor PLX51107 in Combination with Azacitidine in Patients with Relapsed/Refractory Myeloid Malignancies. Clin Cancer Res. 2023 11 01; 29(21):4352-4360.
Score: 0.032
-
Impact of type of induction therapy on outcomes in older adults with AML after allogeneic stem cell transplantation. Blood Adv. 2023 07 25; 7(14):3573-3581.
Score: 0.032
-
Undetectable measurable residual disease is associated with improved outcomes in AML irrespective of treatment intensity. Blood Adv. 2023 07 11; 7(13):3284-3296.
Score: 0.031
-
Ultrasensitive NGS MRD assessment in Ph+?ALL: Prognostic impact and correlation with RT-PCR for BCR::ABL1. Am J Hematol. 2023 08; 98(8):1196-1203.
Score: 0.031
-
Early mortality in acute myeloid leukemia with KMT2A rearrangement is associated with high risk of bleeding and disseminated intravascular coagulation. Cancer. 2023 06 15; 129(12):1856-1865.
Score: 0.031
-
The role of allogeneic transplant for adult Ph+ ALL in CR1 with complete molecular remission: a retrospective analysis. Blood. 2022 11 17; 140(20):2101-2112.
Score: 0.030
-
Clinical outcomes and impact of therapeutic intervention in patients with acute myeloid leukemia who experience measurable residual disease?(MRD) recurrence following MRD-negative remission. Am J Hematol. 2022 Nov; 97(11):E408-E411.
Score: 0.030
-
Blinatumomab maintenance after allogeneic hematopoietic cell transplantation for B-lineage acute lymphoblastic leukemia. Blood. 2022 03 24; 139(12):1908-1919.
Score: 0.029
-
Clinical outcome of allogeneic stem cell transplantation in patients with B-cell lymphoid malignancies following treatment with targeted small molecule inhibitors. Leuk Lymphoma. 2022 04; 63(4):885-893.
Score: 0.029
-
Value of measurable residual disease monitoring in patients with acute promyelocytic leukemia in the era of frontline 'chemotherapy-free' therapy. Leuk Lymphoma. 2022 03; 63(3):672-675.
Score: 0.028
-
Clinical and molecular characterization of myeloid sarcoma without medullary leukemia. Leuk Lymphoma. 2021 12; 62(14):3402-3410.
Score: 0.028
-
Nine-Year Follow-up of Patients with Relapsed Follicular Lymphoma after Nonmyeloablative Allogeneic Stem Cell Transplant and Autologous Transplant. Clin Cancer Res. 2021 11 01; 27(21):5847-5856.
Score: 0.028
-
Inotuzumab Ozogamicin for Relapsed/Refractory Acute Lymphoblastic Leukemia in the INO-VATE Trial: CD22 Pharmacodynamics, Efficacy, and Safety by Baseline CD22. Clin Cancer Res. 2021 05 15; 27(10):2742-2754.
Score: 0.027
-
Venetoclax with decitabine vs intensive chemotherapy in acute myeloid leukemia: A propensity score matched analysis stratified by risk of treatment-related mortality. Am J Hematol. 2021 03 01; 96(3):282-291.
Score: 0.026
-
Efficacy of inotuzumab ozogamicin in patients with Philadelphia chromosome-positive relapsed/refractory acute lymphoblastic leukemia. Cancer. 2021 03 15; 127(6):905-913.
Score: 0.026
-
Impact of number of cycles on outcomes of patients with relapsed or refractory acute lymphoblastic leukaemia treated with inotuzumab ozogamicin. Br J Haematol. 2020 11; 191(3):e77-e81.
Score: 0.026
-
Salvage Therapy Outcomes in a Historical Cohort of Patients With Relapsed or Refractory Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk. 2020 11; 20(11):e871-e882.
Score: 0.025
-
Recent Advances in Managing Acute Lymphoblastic Leukemia. Am Soc Clin Oncol Educ Book. 2020 May; 40:330-342.
Score: 0.025
-
Disseminated cytomegalovirus infection with bilateral adrenal pseudotumors masquerading as recurrent hematologic malignancy. Infection. 2020 Jun; 48(3):477-481.
Score: 0.025
-
Maintenance therapy in AML: The past, the present and the future. Am J Hematol. 2019 11; 94(11):1254-1265.
Score: 0.024
-
Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study. Cancer. 2019 07 15; 125(14):2474-2487.
Score: 0.023
-
Phase 1/2 study of DFP-10917 administered by continuous intravenous infusion in patients with recurrent or refractory acute myeloid leukemia. Cancer. 2019 05 15; 125(10):1665-1673.
Score: 0.023
-
Late relapse in acute myeloid leukemia (AML): clonal evolution or therapy-related leukemia? Blood Cancer J. 2019 01 16; 9(2):7.
Score: 0.023
-
Tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: a single-institution experience. J Hematol Oncol. 2019 01 03; 12(1):1.
Score: 0.023
-
The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia. Cancer. 2019 05 01; 125(9):1470-1481.
Score: 0.023
-
A Pilot Phase II Study of Erlotinib for the Treatment of Patients with Relapsed/Refractory Acute Myeloid Leukemia. Acta Haematol. 2018; 140(1):30-39.
Score: 0.022
-
Phase 3 results for vosaroxin/cytarabine in the subset of patients =60 years old with refractory/early relapsed acute myeloid leukemia. Haematologica. 2018 11; 103(11):e514-e518.
Score: 0.022
-
Clearance of Somatic Mutations at Remission and the Risk of Relapse in Acute Myeloid Leukemia. J Clin Oncol. 2018 06 20; 36(18):1788-1797.
Score: 0.022
-
Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies. Am J Hematol. 2018 03; 93(3):401-407.
Score: 0.021
-
Dose, schedule, safety, and efficacy of guadecitabine in relapsed or refractory acute myeloid leukemia. Cancer. 2018 01 15; 124(2):325-334.
Score: 0.021
-
Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: results from the open-label, randomised, phase 3 INO-VATE study. Lancet Haematol. 2017 Aug; 4(8):e387-e398.
Score: 0.021
-
Relapse risk and survival in patients with FLT3 mutated acute myeloid leukemia undergoing stem cell transplantation. Am J Hematol. 2017 Apr; 92(4):331-337.
Score: 0.020
-
Significance of recurrence of minimal residual disease detected by multi-parameter flow cytometry in patients with acute lymphoblastic leukemia in morphological remission. Am J Hematol. 2017 Mar; 92(3):279-285.
Score: 0.020
-
Activity of the oral mitogen-activated protein kinase kinase inhibitor trametinib in RAS-mutant relapsed or refractory myeloid malignancies. Cancer. 2016 06 15; 122(12):1871-9.
Score: 0.019
-
Acute promyelocytic leukemia presented as a relapse of acute myeloid leukemia. Am J Hematol. 2016 Jun; 91(4):E274-6.
Score: 0.019
-
Early T-cell precursor acute lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) in adolescents and adults: a high-risk subtype. Blood. 2016 Apr 14; 127(15):1863-9.
Score: 0.019
-
A Phase II Study of Coltuximab Ravtansine (SAR3419) Monotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk. 2016 Mar; 16(3):139-45.
Score: 0.019
-
A Phase I/II Study of the mTOR Inhibitor Everolimus in Combination with HyperCVAD Chemotherapy in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia. Clin Cancer Res. 2015 Jun 15; 21(12):2704-14.
Score: 0.018
-
Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed acute myeloid leukemia and acute lymphoblastic leukemia. Haematologica. 2015 Jul; 100(7):927-34.
Score: 0.018
-
Advances in the treatment of relapsed/refractory acute lymphoblastic leukemia: a case study compendium. Clin Adv Hematol Oncol. 2014 Dec; 12(12 Suppl 20):8-18, 1.
Score: 0.017
-
Very high levels of lactate dehydrogenase at diagnosis predict central nervous system relapse in acute promyelocytic leukaemia. Br J Haematol. 2015 May; 169(4):595-7.
Score: 0.017
-
Phase II study of methotrexate, vincristine, pegylated-asparaginase, and dexamethasone (MOpAD) in patients with relapsed/refractory acute lymphoblastic leukemia. Am J Hematol. 2015 Feb; 90(2):120-4.
Score: 0.017
-
A phase I/II study of the Janus kinase (JAK)1 and 2 inhibitor ruxolitinib in patients with relapsed or refractory acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2015 Mar; 15(3):171-6.
Score: 0.017
-
BFR (bendamustine, fludarabine, and rituximab) allogeneic conditioning for chronic lymphocytic leukemia/lymphoma: reduced myelosuppression and GVHD. Blood. 2014 Oct 02; 124(14):2306-12.
Score: 0.017
-
Safety and clinical activity of 5-aza-2'-deoxycytidine (decitabine) with or without Hyper-CVAD in relapsed/refractory acute lymphocytic leukaemia. Br J Haematol. 2014 Nov; 167(3):356-65.
Score: 0.017
-
Cytogenetics, donor type, and use of hypomethylating agents in myelodysplastic syndrome with allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2014 Oct; 20(10):1618-25.
Score: 0.017
-
Phase II trial of hyper CVAD and dasatinib in patients with relapsed Philadelphia chromosome positive acute lymphoblastic leukemia or blast phase chronic myeloid leukemia. Am J Hematol. 2014 Mar; 89(3):282-7.
Score: 0.016
-
Patient-driven discontinuation of tyrosine kinase inhibitors: single institution experience. Leuk Lymphoma. 2014 Dec; 55(12):2879-86.
Score: 0.016
-
Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia. Cancer. 2013 Aug 01; 119(15):2728-36.
Score: 0.016
-
Phase II trial of vorinostat with idarubicin and cytarabine for patients with newly diagnosed acute myelogenous leukemia or myelodysplastic syndrome. J Clin Oncol. 2012 Jun 20; 30(18):2204-10.
Score: 0.015
-
Phase 1/2 study to assess the safety, efficacy, and pharmacokinetics of barasertib (AZD1152) in patients with advanced acute myeloid leukemia. Blood. 2011 Dec 01; 118(23):6030-6.
Score: 0.014
-
Defining the course and prognosis of adults with acute lymphocytic leukemia in first salvage after induction failure or short first remission duration. Cancer. 2010 Dec 15; 116(24):5568-74.
Score: 0.013
-
Kinase domain point mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia emerge after therapy with BCR-ABL kinase inhibitors. Cancer. 2008 Sep 01; 113(5):985-94.
Score: 0.011
-
Validation of the European Prognostic Index for younger adult patients with acute myeloid leukaemia in first relapse. Br J Haematol. 2006 Jul; 134(1):58-60.
Score: 0.010